Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. PODCAST with Dr. David Miklos about ibrutinib in combination with corticosteroids in graft-versus-host disease

2. Significant overall survival benefit with daratumumab, lenalidomide and dexamethasone in transplant-ineligible
    newly diagnosed multiple myeloma

3. Confirmed real-life efficacy of CAR T-cell therapy in a French DLBCL registry

4. Sustained improvements in patient-reported outcomes with sutimlimab in patients with cold agglutinin disease

5. Significant improvement in mean factor IX activity with etranacogene dezaparvovec for haemophilia B